Literature DB >> 8144911

Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.

L Polonelli1, F De Bernardis, S Conti, M Boccanera, M Gerloni, G Morace, W Magliani, C Chezzi, A Cassone.   

Abstract

The principles of idiotypic (Id) vaccination were used to immunize against vaginitis caused by Candida albicans, a widespread and sometimes intractable disease in women. To this aim, a murine mAb (KT4, IgG1) neutralizing in vitro the anti-Candida activity of a yeast killer toxin (YKT) was used as an Id vaccine to elicit Abs with toxin-like activity in a rat vaginitis model. Nonimmunized and isotype-matched, irrelevant mAb-immunized rats served as controls. An effective protection was obtained in Id-vaccinated animals, as demonstrated by a highly significant decrease in vaginal Candida CFU compared with controls. The protection was associated with rising vaginal titers of anti-idiotypic Abs (IdAb), prevalently of the IgA isotype, that were able to passively transfer the protective state to nonimmunized animals. The vaginal IdAb possessed YKT-like activity because they were able to kill in vitro the challenging fungal cells, and this killing was neutralized by the mAb KT4. Overall, these data demonstrate that secretory IdAb elicited by intravaginal Id vaccination with mAb KT4 protected the rats from the infectious challenge with Candida albicans by molecular mimicking YKT activity as its internal image.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144911

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Yeast killer systems.

Authors:  W Magliani; S Conti; M Gerloni; D Bertolotti; L Polonelli
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Immune defence against Candida fungal infections.

Authors:  Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Bart-Jan Kullberg; Frank L van de Veerdonk
Journal:  Nat Rev Immunol       Date:  2015-09-21       Impact factor: 53.106

3.  Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.

Authors:  Dakshnamurthy Selvakumar; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

5.  Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system.

Authors:  Marcello Donini; Chiara Lico; Selene Baschieri; Stefania Conti; Walter Magliani; Luciano Polonelli; Eugenio Benvenuto
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

Review 6.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

7.  Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii.

Authors:  N Séguy; J C Cailliez; P Delcourt; S Conti; D Camus; E Dei-Cas; L Polonelli
Journal:  Mol Med       Date:  1997-08       Impact factor: 6.354

8.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.

Authors:  Carla Bromuro; Antonella Torosantucci; Paola Chiani; Stefania Conti; Luciano Polonelli; Antonio Cassone
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Universal vaccines: shifting to one for many.

Authors:  Antonio Cassone; Rino Rappuoli
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.